Skip to content

Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects

Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04431206
Enrollment
7
Registered
2020-06-16
Start date
2020-11-04
Completion date
2020-11-25
Last updated
2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Osteoarthritis, Knee

Brief summary

This is a study of participants that will receive an intravenous (IV) infusion of oxytocin (naturally occurring hormone that is made in the brain). In this study healthy volunteers and people with knee arthritis so severe that they may need joint replacement are recruited for a one day study. Each study participant will have an IV catheter placed. After placement of the IV catheter oxytocin will be given by IV infusion. Investigators will perform some tests to evaluate how oxytocin changes perceptions on the skin. Investigators will study a painful perception by placing a probe on the skin and heating it to 113 -117 degrees Fahrenheit (F) for 5 minutes. Each study participant will score any pain that is experienced on a 0 to 10 scale, and most people find that pain rises during the 5 minutes, but remains mild, usually around only 1 or 2 on the 0 to 10 scale. The 5 minute heating temperature will be determined according to the subjects pain rating during the screening visit. The main goal of the study is to determine the effect of oxytocin during and after a fixed rate intravenous infusion on reduction in pain to a sustained heat stimulus in order to generate a model for peripheral analgesia.

Detailed description

In this study healthy people or those with knee arthritis so severe that they may need joint replacement are recruited for a one day study. Study participants will come to the Clinical Research Unit (CRU) and one intravenous (IV) catheter will be inserted in the forearm for oxytocin infusion. Participants in this study will receive oxytocin at a steady rate for 30 minutes. This information will be analyzed by another group at Stanford University in the Pharmacokinetic/Pharmacodynamic (PK/PD) Core part of this application. Mathematics will be utilized to calculate how quickly oxytocin moves from the blood to where it reduces pain. Investigators will also do a pain test to determine how much oxytocin reduces pain. For this Investigators will place a probe on the skin and heat it to 113 - 117 degrees for 5 minutes. Study participants will score any pain they feel on a 0 to 10 scale, and most people find that pain rises during the 5 minutes, but remains mild, usually around only 1 or 2 on the 0 to 10 scale.

Interventions

DRUGOxytocin

Oxytocin, 8.2 IU, administered by 30minute IV infusion starting at time 0

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

All arms receive the same IV oxytocin 30-minute infusion. Participants are randomly assigned for heat pain testing every 15 min for 60 min beginning at either 2, 5, 7, or 10 minutes from the beginning of the IV oxytocin infusion.

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male or female \> 18 and \< 75 years of age, Body Mass Index (BMI) \<40. 2. Generally in good health as determined by the Principal Investigator based on prior medical history, American Society of Anesthesiologists physical status 1, 2, or 3. 3. For healthy volunteers, normal blood pressure (systolic 90-140 mmHg; diastolic 50-90 mmHg) resting heart rate 45-100 beats per minute) without medication. For knee arthritis subjects, normal blood pressure or, for those with hypertension, pressure controlled with anti-hypertensives and with a resting heart rate 45-100 beats per minute. 4. Female subjects of child-bearing potential and those \< 1 year post-menopausal, must be practicing highly effective methods of birth control such as hormonal methods (e.g., combined oral, implantable, injectable, or transdermal contraceptives), double barrier methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal jellies or cream), or total abstinence from heterosexual intercourse for a minimum of 1 full cycle before study drug administration.

Exclusion criteria

1. Hypersensitivity, allergy, or significant reaction to any ingredient of Pitocin® 2. Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the Principal Investigator, would place the subject at increased risk (active gynecologic disease in which increased tone would be detrimental e.g., uterine fibroids with ongoing bleeding), compromise the subject's compliance with study procedures, or compromise the quality of the data 3. Women who are pregnant (positive result for serum pregnancy test at screening visit), women who are currently nursing or lactating, women that have been pregnant within 2 years 4. Subjects with neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain medications on a daily basis. 5. Subjects with current or history of ventricular tachycardia, atrial fibrillation or prolonged QT interval. 6. Subjects with past or current history of hyponatremia or at risk for hyponatremia; anyone taking thiazide diuretics, loop diuretics, combination diuretics, lithium, carbamazepine, enalapril, Ramipril, celecoxib, temazepam, gliclazide, glimepiride, glibenclamide, glipizide, omeprazole, pantoprazole, desmopressin, SSRI's, MAOI, or the recreational drug ecstasy. 7. Subjects with a known latex allergy. 8. Subjects with a pain score rating of 1 or less during the initial training session to a 5 minute heating of 45°C- 47 °C to the lower calf.

Design outcomes

Primary

MeasureTime frameDescription
First Verbal Pain Score After Beginning IV Oxytocin Infusion2-10 minutes after starting oxytocin infusion, depending on ArmPain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.
Second Verbal Pain Score After Beginning IV Oxytocin Infusion17-25 minutes after starting oxytocin infusion, depending on ArmPain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.
Third Verbal Pain Score After Beginning IV Oxytocin Infusion32-40 minutes after starting oxytocin infusion, depending on ArmPain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.
Fourth Verbal Pain Score After Beginning IV Oxytocin Infusion47-55 minutes after starting oxytocin infusion, depending on ArmPain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.
Fifth Verbal Pain Score After Beginning IV Oxytocin Infusion62-70 minutes after starting oxytocin infusion, depending on ArmPain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.

Countries

United States

Participant flow

Recruitment details

Healthy participants were recruited from the community from October 15, 2020 through November 15, 2020 via IRB-approved advertisements and IRB-approved lists of previous participants who agreed to be contacted for future studies. They were recruited by phone and provided written informed consent at the day of the training visit.

Participants by arm

ArmCount
Verbal Pain Score at 2 Minutes
Verbal pain score is recorded at the end of 5 minutes of heating the skin. In this arm the first score is obtained at 2 minutes after starting the intervention, then every 15 minutes for 60 minutes Oxytocin: Oxytocin, 8.2 IU, administered by 30minute IV infusion starting at time 0
2
Verbal Pain Score at 5 Minutes
Verbal pain score is recorded at the end of 5 minutes of heating the skin. In this arm the first score is obtained at 5 minutes after starting the intervention, then every 15 minutes for 60 minutes Oxytocin: Oxytocin, 8.2 IU, administered by 30minute IV infusion starting at time 0
1
Verbal Pain Score at 7 Minutes
Verbal pain score is recorded at the end of 5 minutes of heating the skin. In this arm the first score is obtained at 7 minutes after starting the intervention, then every 15 minutes for 60 minutes Oxytocin: Oxytocin, 8.2 IU, administered by 30minute IV infusion starting at time 0
2
Verbal Pain Score at 10 Minutes
Verbal pain score is recorded at the end of 5 minutes of heating the skin. In this arm the first score is obtained at 10 minutes after starting the intervention, then every 15 minutes for 60 minutes Oxytocin: Oxytocin, 8.2 IU, administered by 30minute IV infusion starting at time 0
2
Total7

Baseline characteristics

CharacteristicVerbal Pain Score at 2 MinutesTotalVerbal Pain Score at 10 MinutesVerbal Pain Score at 7 MinutesVerbal Pain Score at 5 Minutes
Age, Continuous36 years26 years25 years22.5 years34 years
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
2 Participants7 Participants2 Participants2 Participants1 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants1 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants5 Participants2 Participants2 Participants1 Participants
Region of Enrollment
United States
2 participants7 participants2 participants2 participants1 participants
Sex: Female, Male
Female
2 Participants3 Participants0 Participants1 Participants0 Participants
Sex: Female, Male
Male
0 Participants4 Participants2 Participants1 Participants1 Participants
Verbal pain score at the end of 5 minute skin heating3.0 units on a scale3.1 units on a scale2.0 units on a scale3.5 units on a scale5.0 units on a scale

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 20 / 10 / 20 / 2
other
Total, other adverse events
0 / 20 / 10 / 20 / 2
serious
Total, serious adverse events
0 / 20 / 10 / 20 / 2

Outcome results

Primary

Fifth Verbal Pain Score After Beginning IV Oxytocin Infusion

Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.

Time frame: 62-70 minutes after starting oxytocin infusion, depending on Arm

ArmMeasureValue (MEAN)
Verbal Pain Score at 2 MinutesFifth Verbal Pain Score After Beginning IV Oxytocin Infusion3.0 units on a scale
Verbal Pain Score at 5 MinutesFifth Verbal Pain Score After Beginning IV Oxytocin Infusion2.0 units on a scale
Verbal Pain Score at 7 MinutesFifth Verbal Pain Score After Beginning IV Oxytocin Infusion1.5 units on a scale
Verbal Pain Score at 10 MinutesFifth Verbal Pain Score After Beginning IV Oxytocin Infusion0.5 units on a scale
Primary

First Verbal Pain Score After Beginning IV Oxytocin Infusion

Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.

Time frame: 2-10 minutes after starting oxytocin infusion, depending on Arm

ArmMeasureValue (MEAN)
Verbal Pain Score at 2 MinutesFirst Verbal Pain Score After Beginning IV Oxytocin Infusion3.5 units on a scale
Verbal Pain Score at 5 MinutesFirst Verbal Pain Score After Beginning IV Oxytocin Infusion4.0 units on a scale
Verbal Pain Score at 7 MinutesFirst Verbal Pain Score After Beginning IV Oxytocin Infusion3.5 units on a scale
Verbal Pain Score at 10 MinutesFirst Verbal Pain Score After Beginning IV Oxytocin Infusion1.5 units on a scale
Primary

Fourth Verbal Pain Score After Beginning IV Oxytocin Infusion

Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.

Time frame: 47-55 minutes after starting oxytocin infusion, depending on Arm

ArmMeasureValue (MEAN)
Verbal Pain Score at 2 MinutesFourth Verbal Pain Score After Beginning IV Oxytocin Infusion2.0 units on a scale
Verbal Pain Score at 5 MinutesFourth Verbal Pain Score After Beginning IV Oxytocin Infusion3.0 units on a scale
Verbal Pain Score at 7 MinutesFourth Verbal Pain Score After Beginning IV Oxytocin Infusion2.0 units on a scale
Verbal Pain Score at 10 MinutesFourth Verbal Pain Score After Beginning IV Oxytocin Infusion1.0 units on a scale
Primary

Second Verbal Pain Score After Beginning IV Oxytocin Infusion

Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.

Time frame: 17-25 minutes after starting oxytocin infusion, depending on Arm

ArmMeasureValue (MEAN)
Verbal Pain Score at 2 MinutesSecond Verbal Pain Score After Beginning IV Oxytocin Infusion1.5 units on a scale
Verbal Pain Score at 5 MinutesSecond Verbal Pain Score After Beginning IV Oxytocin Infusion3.0 units on a scale
Verbal Pain Score at 7 MinutesSecond Verbal Pain Score After Beginning IV Oxytocin Infusion1.5 units on a scale
Verbal Pain Score at 10 MinutesSecond Verbal Pain Score After Beginning IV Oxytocin Infusion1.0 units on a scale
Primary

Third Verbal Pain Score After Beginning IV Oxytocin Infusion

Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature is determined by pain rating during screening visit.

Time frame: 32-40 minutes after starting oxytocin infusion, depending on Arm

ArmMeasureValue (MEAN)
Verbal Pain Score at 2 MinutesThird Verbal Pain Score After Beginning IV Oxytocin Infusion3.0 units on a scale
Verbal Pain Score at 5 MinutesThird Verbal Pain Score After Beginning IV Oxytocin Infusion4.0 units on a scale
Verbal Pain Score at 7 MinutesThird Verbal Pain Score After Beginning IV Oxytocin Infusion1.0 units on a scale
Verbal Pain Score at 10 MinutesThird Verbal Pain Score After Beginning IV Oxytocin Infusion1.0 units on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026